A process for the preparation of keratin nano-peptides and use thereof
The two-stage alkaline-enzymatic hydrolysis process and multilevel filtration system efficiently produce keratin nano-peptides from poultry feathers, addressing the inefficiencies of existing methods by reducing costs and environmental impact, and enhancing yield for industrial applications.
Patent Information
- Application Number
- PCT/IN2024/050609
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
Current methods for extracting keratin from poultry feathers are costly, time-consuming, and environmentally harmful, leading to inefficient production and loss of essential amino acids, with existing processes being unsuitable for scalable industrial application.
A two-stage alkaline-enzymatic hydrolysis process using a novel enzyme cocktail and multilevel filtration system to produce water-soluble and oil-soluble keratin nano-peptides, reducing chemical requirements and maintaining the functional properties of natural keratin.
The process is economically viable, environmentally friendly, and increases the yield of keratin peptides, making it commercially scalable while retaining the natural properties of keratin, suitable for use in nutraceuticals, pharmaceuticals, and cosmetics.
Smart Images

Figure IMGF000021_0001 
Figure IMGF000022_0001 
Figure IMGF000022_0002
Abstract
Description
[0001] A Process for The Preparation of Keratin Nano-Peptides and use thereof
[0002] Field of the Invention
[0003] The present invention broadly relates to the field of biotechnology. More particularly, the present invention relates to a process for preparing water soluble and / or oil- soluble keratin nano-peptides and the water-soluble and / or oil soluble keratin nano-peptides obtained thereof. Further, the present invention also relates to the use of such keratin nano-peptides in nutraceutical, pharmaceutical and cosmetic industries. Moreover, the present invention also provides an enzyme cocktail for the hydrolysis of keratin from poultry feathers.
[0004] Background Art
[0005] Keratin is the collective name for a family of tough proteins which are found in a number of structures. Keratin is of significant commercial value and is used in a number of industries especially the cosmetic, nutraceutical and pharmaceutical industry. One source of keratin in particular — feathers — is produced in vast quantities by the poultry industry. Feathers represent from 5% to 7% of the body weight of chickens. These important by-products of the poultry industry are produced in millions of tons annually throughout the world. Chicken feathers are approximately half feather fibre (barbs) and half quill (rachis) by weight. The quill is the stiff central core, to which the soft and interlocking fibres are branched. Both feather fibre and quill are made of keratin (about 90% by weight). The keratin is an insoluble and highly durable protein found in hair, hoofs and horns of animals. Fibres from chicken feathers have several distinctive features such as: surface toughness, flexibility, high length to diameter ratio, hydrophobicity and a highly organized morphology characterized by its complex hierarchical structure. Further the protein fibres are effectively self-sustainable, biodegradable and continuously renewable due to their natural biopolymer origin.
[0006] Despite the unique properties, feathers are largely disposed of by incineration which leads to environmental problems. Recycling feathers, which are source of biopolymers have been the objective of much research because of their high protein content, biodegradability and biocompatibility. Poultry feathers typically contain approximately 90% protein in the form of keratin. Keratin, a fibrous protein that is the main structural element of feather by-product is used in a wide range of industries, including food, textiles, pharmaceutical, cosmetics, leather, and poultry processing (Donato and Mija 2020; Sharma S, et., al, 2017; Lasekan A, 2013). There are two main types of keratin, a- and P-keratin. The a-keratin are mostly present in the hair, wool, horns, nails, claws, and hooves of mammals. Poultry feathers typically contain approximately 90% protein in the form of P-keratin.
[0007] Keratin proteins have a high concentration of the sulphur-containing amino acid cysteine, which helps to create disulfide bridges between the individual molecules and contributes to the hard structure of keratin, thus, it can be challenging to digest and degrade. Therefore, the degradation of feathers can offer a low-cost source of easily absorbed protein and amino acids (McCasland and Richardson 1966). As a renewable and biodegradable biopolymer, this keratin could also be applied in a more sustainable way in value added applications by the conversion of the complex feather structure into a more appropriate form of small peptide and high-value compounds or products. Unfortunately, currently available methods to extract this nutrient are very expensive. Therefore, most of the feather waste streams are simply disposed of in landfills or through burning, which can cause negative environmental effects and reduce the sustainability of the primary commercial process.
[0008] In 2002 approximately 49 billion chickens were utilized in the poultry industry. Poultry industries around the globe generate huge amounts of solid by-products such as feather, feet, and bones. Disposal of such a large number of feathers in landfills leads to environmental pollutions (Poole et al.2008; Tesfaye et al. 2017, Feroz et al. 2020). Thus, utilization of the chicken feather waste to generate the valuable products becomes more essential. However, keratin must be cleaved before its protein content can be digested by animals. Degradation of feathers can therefore provide an inexpensive source of digestible protein and amino acids.
[0009] Currently available methods to produce keratin hydrolysate from feather are more expensive (Zhang, et., al, 2013; Ruirui Wang and Hui Tong, 2022). Certain procedures result in incomplete hydrolysis, contamination with undesired amino acids, and not produces highly digestible products, which lead to loss of nutritionally important essential amino acids of keratin hydrolysate (Dalev et al. 1997, Barone & Schmidt 2006, Schrooyen et al, 2001a). In addition, chemical hydrolysis leads to destruction of the native structure of keratin. Acidic hydrolysis is highly efficient, but causes loss of some essential amino acids, e.g., tryptophan. The alkaline hydrolysis process is slower and can be incomplete, but the loss of amino acids is lower.
[0010] “Shindai Method” is one of the most commonly used extraction protocols (Sinkiewicz 1 , 2017; Yin XC, 2013; Nakamura et al. 2002) in which chicken feather samples incubated with a specific buffer. However, this process is time - consuming and costly due to the expensive chemicals but was predominantly used as the recovery yield of protein was high.
[0011] Moreover, the conventionally known processes are complicated and comparatively difficult. Further, the time required for each of the process is long and the cost of these methods are high, and the yield of the product is poor which is not economically feasible. Most of the conventional methods of keratin extraction include reduction, oxidation acidic hydrolysis, alkaline hydrolysis, sulphitolysis, enzymatic hydrolysis, and so on. These methods require various environmentally harmful solvents, such as sodium sulphide, metabisulphite, 2-mercaptoethanol, Urea, HCL and so on. The existing methods create some difficulties such as high pollution, time-consuming, high cost, Low yield, high energy consumption and cause risks for health and environment, which are not suitable for the scaling up of keratin production economically (Zhang, J ,et.,al, 2013; Ruirui Wang and Hui Tong, 2022). Thus, there is still a need for an economically viable and environment friendly method for the extraction of keratin containing materials that can be used to provide a range of keratin- based commercial products.
[0012] Over the years, keratin can be extracted using several conventional methods such as thermal hydrolysis, chemical hydrolysis, enzymatic treatment, dissolution in ionic liquids, microwave technique, and steam explosion technique. The procedures that are currently in use are complex and comparatively challenging since they use reducing agents and other chemicals for keratin extraction, followed by hydrolysis under acidic or alkaline conditions at high temperature. These methods can be used effectively at the lab scale, but to scale up a process up to the pilot plant or industrial scale, factors like the costs of chemicals, elevated temperature and time required may become their limitations. The existing methods mostly focus on reducing agents which cleaves disulfide bond (-S-S-) of the cystine residue to give a thiol group (-SH) in initial step.
[0013] Traditionally, for the preparation of oil-soluble keratin peptides, the Schotten Baumann reaction was carried out to chemically synthesize amides from acyl chlorides and amines. This is a base catalyzed reaction wherein the base is required to shift the equilibrium towards the formation direction of amides. Further, the use of acid chlorides is one of the most widely used Wacylating agents for amide bond formation that are employed widely throughout both academia and industry. However, problems associated with the reaction of amines with acid chlorides can include highly exothermic reactions, the release of an equivalent of HC1, and premature hydrolysis of sensitive acid chloride reagents. One of the biggest difficulties encountered is the propensity of chiral a-substituted acid chlorides to undergo racemization under basic conditions, which limits the use of acid chlorides as substrates for peptide synthesis.
[0014] Furthermore, fatty acid chlorides are toxic and corrosive in nature and hence, the existing methods which are mostly dependent on the use of acid chloride as acylating agents are not feasible options. In many such methods, the reactions are carried out at high temperature of methyl esters (such as, for example, methyl myristate or methyl stearate) with various amino acids. However, these reactions are accompanied by decarboxylation and then amidation reactions, to result in the formation of fatty amides exhibiting the side chain of the amino acid, and thus in structures which are not those desired. In another method, the use of a solvent comprising an alcohol functional group makes it probable that an ester will be formed as undesired byproduct. Accordingly, while such processes make it possible to achieve sparingly colored reaction products, but as the process yields undesired by products, there must be step for the removal of the same. Furthermore, in processes with the use of polyols in the solvent medium, make it probable that undesired esters will be formed.
[0015] A particular area of interest is the use of metal catalysts to form amides from a range of starting materials. In addition to metal catalysts, non-metal compounds have also been found to catalyze amidation reactions successfully, with boronic acids and related compounds as the most common examples. As well as these general amidation methods there are also many protocols reported that are specific to the formation of acetamides.
[0016] However, the traditional methods used to synthesize acetamides usually involve the use of activated acylating agents, such as acetic anhydride and acetyl chloride. Although these reagents are cheap, their toxicity and hygroscopic nature make them less than ideal as acylating agents. Many procedures also use metal catalysts, both heterogeneous and homogeneous, which are often expensive and add further purification steps.
[0017] Over the years, keratin can be extracted using several conventional methods such as thermal hydrolysis, chemical hydrolysis, enzymatic treatment, dissolution in ionic liquids, microwave technique, and steam explosion technique. The procedures that are currently in use are complex and comparatively challenging since they use reducing agents and other chemicals for keratin extraction, followed by hydrolysis under acidic or alkaline conditions at high temperature. These methods can be used effectively at the lab scale, but to scale up a process up to the pilot plant or industrial scale, factors like the costs of chemicals, elevated temperature and time required may become their limitations. The existing methods mostly focus on reducing agents which cleaves disulfide bond (-S-S-) of the cystine residue to give a thiol group (-SH) in initial step.
[0018] However, there yet does not exist a viable process for the extraction of oil-soluble keratin peptides. It is known in the art that keratins are resistant to hydrolysis and the accessibility of keratin structures for enzyme is more difficult and hence, the inventors devised a two-stage process was chosen because keratin swelling in an alkaline environment is a favorable factor making disulphide and peptide bonds more accessible to enzyme action. The swelling creates essential access for a denaturing agent to break the disulphide bonds. Cleavage of disulphide bond to thiol group (-SH) is a favorable factor making disulfide and peptide bonds more accessible to enzyme action.
[0019] Therefore, in view of the limitations of the conventional methods, the present inventors have devoted their significant efforts with the aim of a reliable, economical, and eco-friendly method for scalable production of keratin while retaining the functional properties of natural keratin as much as possible, from chicken feather waste. The present invention resolves the problem of the conventional method, reduces the time of the completion of reaction, and improves the yield of the product.
[0020] Thus, the inventors of the present invention have developed a novel process that solves the aforementioned problems in the prior art by providing methods, and compositions that are economically viable for the acylation of keratin (e.g., in feathers) for the enzymatic hydrolysis of keratin (e.g., in feathers) compared to conventional methods and produce digestible and more palatable products. The present invention is focused to achieve an eco-friendly, cost- effective method for the production of keratin peptides while sustaining the functional characteristics of natural keratin.
[0021] In contrast to the prior art, the present inventors have devoted their significant efforts with the aim to achieve a reliable, economical, and eco-friendly method for scalable production of keratin while retaining the functional properties of natural keratin as much as possible, from chicken feather waste. The present invention resolves the problem of the conventional method, reduces the time of the completion of reaction, and improve the yield of the product.
[0022] Ob ject of the Invention An object of the present invention provides a two-step process for the alkaline extraction of water-soluble keratin nano-peptides from poultry feathers.
[0023] An object of the present invention provides a process for the extraction of hydrolyzed keratin nano- peptides from poultry feathers.
[0024] An object of the present invention provides the water-soluble keratin nano-peptides obtained by the two-step process for the alkaline process.
[0025] An object of the present invention provides the oil-soluble keratin nano-peptides obtained by the process of the invention.
[0026] An object of the present invention provides the multilevel filtration process for obtaining the nano-keratin nano-peptide.
[0027] An object of the present invention provides a multi-level filtration system.
[0028] An object of the present invention provides a composition comprising the keratin nano-peptide along with pharmaceutically acceptable excipients, diluent and carriers.
[0029] An object of the present invention provides use of the composition as and when used in the preparation of tissue engineering scaffolds or for preparation of medicated creams or gels for management of 2nd and 3rd degree burns.
[0030] An object of the present invention provides the water-soluble keratin nano-peptide as and when employed in nutraceutical, pharmaceutical and cosmetics industry, or as an excipient for formulation in a drug delivery system.
[0031] An object of the present invention provides the oil-soluble keratin nano-peptide as and when employed in nutraceutical, pharmaceutical and cosmetics industry, or as an excipient for formulation in a drug delivery system.
[0032] BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The accompanying drawings and tables illustrate embodiments of the invention and, together with the description, serve to explain the invention. These drawings are offered by way of illustration and not by way of limitation. Figure 1: SDS-PAGE analysis of keratin hydrolysate and protein standard Marker. It shows wide range molecular weight marker (3.5 - 240 kDa) in Lane: M. Enzymatic hydrolysed peptides in Lanes 1, 2 &3. Keratin nano-peptides 1, 2 & 3 represents keratin hydrolysates prepared in 3 batches. These results show the molecular weight range of keratin hydrolysate protein between 3.5 to 30kDA.
[0034] Figure 2: Thi n-layer chromatography analysis of the keratin hydrolysates.
[0035] Figure 3: Mouse immunized with high dose of Keratin nano-peptides which received Evan’s Blue dye in the tail vein.
[0036] Figure 4: Blood vessels in the mouse’s ear which are stained blue due to the dye injected in the tail vein (arrow pointing to the stained blood vessel)
[0037] Figure 5: The immunizing antigen is injected in the mouse’s ear.
[0038] Figure 6: The mouse’s ear did not show signs of dye leaking post injection of the immunizing agent (arrow pointing to the site of injection).
[0039] Figure 7: Averaged (N=4 mice) optical density due to IgG (circles) and IgE (squares) in various dilutions of the serum of mice immunized with 25 pg doses of Keratin nano-peptides. Error bars depict the standard deviation. The antibody titre (dilution at which the response signal is indistinguishable from the background noise, i.e., when the signal is extinguished) in this case was 10’2.
[0040] Figure 8: shows ELISA results of the mice immunized with the higher dose of 50 pg.
[0041] Figure 9: shows IgG and IgE responses elicited by immunization with 50 pg doses of OVA.
[0042] Figure 10A and 10B: shows In vitro recall response to Keratin nano-peptides of (A): LN cells and (B): spleen cells from only one of four mice immunized with lower dose of Keratin nano- peptides. Cells showed low-level and random proliferation in response to antigen challenge at concentrations ranging from 0.1 to 100 pg / ml. The X-axis is logarithmic (logs). The Y-axis shows indexed proliferation where no proliferation is indicated as 100% (dashed line; i.e., the cell population remained 100% of what was seeded in the well). The average of three replicates are plotted; standard deviation was above 50%, which is larger than the range of the means, and is not plotted as error bars. The (+)ve control (Concanavalin A) induced -300-750% proliferation and is not plotted. Figure 11A and 11B: In vitro recall response to Keratin nano-peptides of (A): LN cells and (B): spleen cells from four mice immunized with the higher dose of Keratin nano-peptides. Cells showed no proliferation in response to antigen challenge at indicated concentrations. There was a statistically non- significant but dose-dependent loss of viability of LN cells. The average proliferation index of four mice is plotted, error bars show standard deviation. The (+)ve control indicated that cells were live and responsive to mitogen challenge.
[0043] Figure 12A and 12B: In vitro recall response to OVA of (A): LN cells and (B): spleen cells from four mice immunized with the OVA. LN cells proliferated in response to antigen challenge at indicated concentrations. There was a statistically non- significant but dosedependent loss of viability of LN cells. The average proliferation index of four mice is plotted, error bars show standard deviation. The (+)ve control indicated that cells were live and responsive to mitogen challenge.
[0044] Figure 13: SEM images of effectiveness of Keratin Nano-peptides in repair of damaged hair with Fiberhance (commercially available product).
[0045] Figure 14: Particle size distribution keratin nano peptides sample in water.
[0046] Detailed Description of the invention
[0047] At the very outset of the detailed description, it may be understood that the ensuing description only illustrates a particular form of this invention. However, such a particular form is only exemplary embodiment, and without intending to imply any limitation on the scope of this invention. Accordingly, the description is to be understood as an exemplary embodiment and teaching of invention and not intended to be taken restrictively.
[0048] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0049] The inventors of the present invention have developed a novel process wherein the first stage extraction of keratin is carried out under mild conditions to loosen tightly packed betasheet structure and efficiently break the peptide bonds of the keratin by enzymatic hydrolysis in second step. The process reduces the requirements of chemicals and their cost that makes it economically and commercially viable. The present invention provides a method for obtaining a good yield in a simple and easy process. Thus, an aspect of the present invention provides a two-stage alkaline-enzymatic hydrolysis for the conversion of chicken feathers into keratin hydrolysate solution.
[0050] The inventors of the present invention have developed a significantly effective enzyme cocktail along with optimized process parameters in terms of temperature, pH and time, that helps in enhancing yield and reducing time of operations thus contributing heavily to making the process commercially workable. Another aspect of the present invention offers a low-cost protease enzyme derived from fungal strain. This offers a distinct advantage over bacterial enzymes because fungi can grow on low-cost substrates and secrete large number of enzymes into culture medium which could ease downstream processing.
[0051] In another important aspect, the present inventors have also developed a novel two- stage process for the production of oil-soluble keratin nano-peptides wherein the first stage comprises a two-step extraction method wherein extraction of keratin is carried out firstly under mild conditions to loosen tightly packed beta-sheet structure and secondly to efficiently break the peptide bonds of the keratin by enzymatic hydrolysis in the second step. The second stage of the process comprises acylation of the enzyme hydrolyzed keratin nano-peptides obtained in the first stage of the process. The process reduces the requirements of chemicals and their cost that makes it economically and commercially viable. The present invention provides a method for obtaining a good yield in a simple and easy process.
[0052] The inventors of the present invention have developed a novel Water Phase Acylation technology by optimizing and standardizing the process where enzyme hydrolyzed keratin nano-peptides are acylated in the water phase itself making it effectively soluble in oil phase up to 25%. The enzyme hydrolyzed keratin nano-peptides in water phase are the most effective and are in their natural form without much denaturation, that typically happens during conventional drying and converting to the powder format. Thus, the technology developed by the present invention keeps nano-peptides in their most natural form. Furthermore, this technology helps in completely removing the step of drying the product present in the conventional methods and brings down the operational complexity which in turn makes it commercially viable and competitive.
[0053] In another aspect, the inventors of the present invention have also developed an in house standardized and optimized Multilevel Filtration Technology that ensures that the obtained keratin peptides are standard product with a consistent size range of 0.5kDa to 30kDa. This is also critical in terms of final product functional delivery as nano peptides have a lot of function in pharmaceutical industry. The multilevel filtration technology means a set of filtration system that has been designed in a way where the product after the hydrolysis process passes through this system developed by the inventors. The system involves a strata of vortex filtration system in combination with multiple levels of micro and nano filtration systems placed in a way which not only helps concentrating the peptides but also helps in getting a concentrated peptides within a desired range of size in a consistent manner with a much better yield. This system helps making a commercially viable and functionally deliverable product.
[0054] Another important aspect of the present invention relates to water soluble and oil soluble hydrolyzed keratin peptides with a wide size molecular weight range distribution from 500Da to 30kDA. This is the characteristic required in different industrial usage like cosmetics, pharmaceuticals and nutraceuticals.
[0055] Embodiments of the invention:
[0056] An important embodiment of the present invention provides a process for preparing a keratin nano peptides, the process comprising the steps of: a. collecting poultry feathers, followed by hot water rinsing, sterilization and dewaxing to enhance the surface porosity of the feathers obtained in step (a); b. drying and grinding the feathers of step (a) to obtain a fine uniform powder; c. mixing the powder obtained in step (b) with an alkaline solvent and incubated at 45°C- 65°C for 1 to 3 hours in a blender with continuous stirring at 100-200 rpm to obtain the alkaline mixture; d. enzymatically treating the alkaline mixture obtained in step (c) with an enzyme cocktail at 37°C- 50°C for 3 to 5 hours for enzymatic hydrolysis to obtain the post-enzyme hydrolysis extract e. processing the post-enzyme hydrolysis extract of step (d) to obtain the keratin nano peptides wherein the said keratin nano peptides are either water soluble or oil soluble keratin nano peptides. Another important embodiment of the present invention provides that the processing step (e) comprises passing the post-enzyme hydrolysis extract obtained in step (d) through a multilevel filtration system to obtain water soluble keratin nano peptides.
[0057] In a preferred embodiment of the present invention provides that the multilevel filtration system comprises the steps of passing the enzymatically treated alkaline mixture in a sequential manner through rotary filter, a microfiltration unit and finally through a nanofiltration unit to obtain purified keratin nano-peptides.
[0058] Yet another important embodiment of the present invention provides that the processing step (e) comprises a) mixing the post-enzyme hydrolysis extract obtained in step (d) with a fatty acid ester in a vessel at 60-80°C overnight. b) adding a 2ndfatty acid ester dissolved in an alcohol to the reaction mixture obtained in step (a) for 3-5 hours at temperature 60-80°C; c) raising the temperature to 80-90°C of the solution obtained in step (b) for 2- 6 hours; and d) filtering the solution obtained in step (c) to obtain the oil soluble keratin nano peptides.
[0059] A preferred embodiment of the present invention provides that the oil- soluble keratin nano-peptide obtained in step (d) is filtered with an inline filter membrane.
[0060] Another embodiment of the present invention provides that the enzyme cocktail of step (d) is an enzymatic concoction of at least two or more fungal or plant protease enzymes.
[0061] Another embodiment of the present invention provides that the two or more protease enzymes are in the concentration range of 0.2 to 3.5.
[0062] Another embodiment of the present invention provides that the fungal protease enzymes are obtained from the group consisting of genera Aspergillus, Penicillium, or Rhizopus. Another embodiment of the present invention provides that the protease in enzyme cocktail is obtained from at least 2 proteases selected from aspartic, glutamic, metalloproteases, cysteine, serine, and threonine proteases or combinations thereof.
[0063] Another embodiment of the present invention provides that the alkaline solvent of step (c) is selected from sodium hydroxide, potassium hydroxide and calcium hydroxide.
[0064] Another embodiment of the present invention provides that the alkaline solvent is in the range of 1-5%.
[0065] Yet another important embodiment of the present invention provides a multilevel filtration process for obtaining the nano-keratin nano- peptide, wherein the process comprises the steps of: a) passing the solution post enzyme hydrolysis extract obtained in step (e) of the process of preparing the keratin nano-peptides through a rotary filter having a sieve of at most 50p to obtain a solution free of any bigger size particles, b) passing the solution of step (a) through a microfiltration unit a ceramic filter of at most 0.2 microns and c) passing the extract from step (b) through a nanofiltration unit with a cut off of 300 kDa molecular level size to obtain the final concentrated product which is a water-soluble keratin nano peptides.
[0066] Yet another important embodiment of the present invention provides a multi-level filtration system comprising: a rotary filter (100) having a sieve size of 50 microns; microfiltration unit having a sieve size of .02 microns; and nanofiltration unit having a sieve size of a minimum of 300 kDa; wherein the concentrate is transported from the feed storage tank (101) through a recirculation pump (102) to the ceramic membrane system (103); the permeate is collected in the permeate tank (104) and transported by the feed pump (105) to the MCF (106); the nanofiltration high pressure pump (107) transfers the permeate to the nanofiltraton membrane system (108) and the concentrate is collected; the permeate is then stored in a permeate storage tank (109).
[0067] Yet another important embodiment of the present invention provides a water-soluble keratin nano- peptide obtained from the process for preparing the keratin nano peptides wherein the keratin nano- peptide has a molecular weight range of 500Da to 30kDa.
[0068] Yet another important embodiment of the present invention provides an oil-soluble keratin nano- peptide obtained from the process for preparing the keratin nano peptides wherein the keratin nano- peptide has a molecular weight range of 500Da to 30kDa.
[0069] A preferred embodiment of the present invention provides that the size of the keratin nano-peptides is in the range of l-5nm.
[0070] Yet another important embodiment of the present invention provides a composition comprising the keratin nano-peptide along with pharmaceutically acceptable excipients, diluent and carriers.
[0071] Another embodiment of the present invention provides that the pharmaceutically acceptable excipients or carriers are any selected from disaccharides, polysaccharides, sugar alcohol, gum, humectants, emulsifiers, emollients, preservatives, water, cellulose starch, maltodextrin, essential oils or combinations thereof.
[0072] Another embodiment of the present invention provides that the composition is formulated in the form of shampoos, serums, hair and scalp care products, supplements and nutraceutical formulation.
[0073] Yet another important embodiment of the present invention provides the keratin nano- peptide as and when employed in nutraceutical, pharmaceutical and cosmetics industry, or as an excipient for formulation in a drug delivery system.
[0074] Yet another important embodiment of the present invention provides the composition as and when used in the preparation of tissue engineering scaffolds or for preparation of medicated creams or gels for management of 2nd and 3rd degree bums.
[0075] Another embodiment of the present invention provides that the keratin nano particle as and when used in biomaterials such as sponges, hydrogels, wound patches, films, and fibres which have been created for biomedical applications. Another embodiment of the present invention provides that the keratin nano particle as and when used in the field of nanoparticle medication delivery wherein the protein polymers and protein composite materials are suitable for drug delivery systems and can improve the controller release or targeting mechanism.
[0076] Another embodiment of the present invention provides that the keratin nano particle is used as a protein supplement.
[0077] Advantages:
[0078] The present invention demonstrates the following advantages:
[0079] • Environmentally friendly,
[0080] • Non-toxic,
[0081] • Cost-effective,
[0082] • Increased yield of the protein,
[0083] • Commercially scalable.
[0084] The foregoing broadly outlines the features and technical advantages of the present disclosure in order that the detailed description of the disclosure that follows may be better understood. It should be appreciated by those skilled in the art that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying the disclosed methods or for carrying out the same purposes of the present disclosure.
[0085] Without limiting the scope of the present invention as described above in any way, the present invention has been further explained through the examples provided below.
[0086] Examples:
[0087] Example 1: Production of water-soluble keratin peptides from poultry feathers
[0088] An appropriate number of feathers from chicken were gathered. The feathers were washed and then the amino acid composition was determined by HPLC method. Feathers from chicken were gathered from either poultry processing industry or from the poultry Farms. Rinsing the feathers with hot water followed by sterilization and dewaxing. The feathers are dewaxed using surfactants such as sodium carbonate and sodium hypochlorite combination as a self- standardized ratio at 36.5 to 40.5°celsius. This was done at selfstandardized feather to surfactants and hypo solution ratio at self- standardized exposure time that helps in expediting the future reactions.
[0089] This was followed by drying to get it to a moisture level of approximately 5-6% to help properly grind to reduce the surface area of the feather when converted to a powdered form. This allows the feather area to be better exposed for further treatments and increase the surface porosity of it.
[0090] Keratin extraction from the feathers was carried out by two-stage alkaline process. In the first stage, feathers were mixed with sodium hydroxide and incubated at 45°C- 65°C for 1 to 3 h in a blender with continuous stirring at 100-200 rpm to obtain the hydrolysate solution. Sodium hydroxide was taken in the range of 1-5%. This solution was then treated with a proteolytic enzyme concoction were added at 37 °C- 50°C / 3 to 5 h in a blender with agitator to obtain the keratin hydrolysate. The concentration of keratin hydrolysate protein was 80.68%, calculated through nitrogen analysis, using Kjeldahl nitrogen determination method (Table- 1).
[0091] Table- 1:
[0092] Further, the amino acid profile of the obtained keratin hydrolysate was also calculated as shown in Table 2. To determine the concentration of amino acids in the keratin hydrolysate, the picomoles of amino acid reported by the chromatographic software was divided by the injection volume. This value was then multiplied by the volume of diluent divided by the volume derivatized.
[0093] Table-2: Amino acid profile of Keratin hydrolysate.
[0094] Example 2: Production of oil-soluble keratin nano-peptides from poultry feathers (Water Phase Acylation)
[0095] Sixty volumes of keratin hydrolysate obtained in step (i) was mixed with 30 volumes of a fatty acid ester i.e., 30% Isopropyl palmitate at 60-80°C and stirred overnight. Further, another fatty acid ester i.e., 10% Isopropyl myristate, was added to reaction mixture for 3-8 h at temperature 60-80°C. The solution obtained was then filtered to get the oil soluble product. The yield of the oil soluble keratin nano-peptides was 85-95% by using the method of the present invention.
[0096] Example 3: Analysis of the water-soluble keratin nano-peptides
[0097] The keratin hydrolysate of example 1 was prepared to analyse its weight and molecular mass. After the hydrolysis step, the obtained keratin protein was broken into small peptides. The size range of peptide was determined through SDS PAGE. Figure 1 shows wide range molecular weight marker (3.5 - 240 kDa) in Lane: M. Enzymatic hydrolysed peptides in Lanes 1, 2 &3. Keratin nano-peptides 1, 2 & 3 represents keratin hydrolysates prepared in 3 batches. These results show the molecular weight range of keratin hydrolysate protein between 3.5 to 30kDA. Further, analysis of the enzymatic keratin hydrolysates was carried out using thin-layer chromatography. The nano-peptides with a lower molecular mass were observed as shown in Figure 2, while no streak was observed in unhydrolyzed keratin.
[0098] Example 4: Multi-level filtration of the keratin hydrolysate to obtain the keratin nano peptides
[0099] The inventors of the present invention have developed and optimized a novel multilevel filtration mechanism which post carrying out the hydrolysis as described in example 2, the separation and concentration of “Nanopeptides / Nano-actives” which were the desired final product parameters in terms of their molecular size in the nanoparticle range (500 Dalton to 30 kDA) was performed using the multi-level filtration system.
[0100] In order to concentrate the nano peptides, post enzyme hydrolysis extract was first passed through a rotary filtration system where bigger size particles were removed while the extract passed through 50-micron sieve. The filtrate was then in continuity passed through the microfiltration unit comprising a ceramic filter of 0.2 microns. Finally, the extract was passed through a nano-filtration unit with a cut off of 300 kDa molecular level size. Here, the hydrolyzed extract was concentrated to the final product which was a water soluble keratin nano-peptides.
[0101] This filtration chain was developed, standardized and operationally optimized to make it a commercially successful process to concentrate “Nanopeptides / nanoactives” which have high biocompatibility / high biological activity & enhanced bio-functionality.
[0102] Example 5: Efficiency of keratin production by the proposed method on comparison with conventionally known methods
[0103] The efficacy of the proposed method of example 1 and 2 was compared with some known methods in the art for the production of water-soluble keratin peptides. Table 3 shows the results of the keratin production by the claimed method and the methods known in the art. The results clearly demonstrate that the proposed method is a reliable, economical, and eco- friendly method for scalable production of keratin while retaining the functional properties of natural keratin as much as possible, from chicken feather waste. Thus, the present invention resolves the problem of the conventional method, reduces the time of the completion of reaction, and improve the yield of the product. Table 3:
[0104] Example 6: Assessment of the Keratin Nano-peptides for human use and consumption
[0105] An in-house study was conducted to assess keratin nano-peptides for skin sensitizing hazard using Genomic Allergen Rapid Detection skin assay (OECD Test Guideline No. 442E). The assay evaluates exposure-induced transcriptional patterns of endpoint specific genomic biomarker signatures in the SenzaCell cell line, following exposure to the keratin nano- peptides.
[0106] The purpose of this study was to assess Keratin Nano-peptides prepared in example 1 and example 2 for skin sensitizing hazard using the Genomic Allergen Rapid Detection (GARDskin assay). The method evaluated the transcriptional patterns of an endpoint- specific genomic biomarker signature, referred to as the GARDskin Genomic Prediction Signature (GPS), in the SenzaCell cell line which was exposed to test chemicals. i. Solubility assessment:
[0107] In this study, the concentration of the test item- Keratin Nano-peptides was expressed in weight-based measures with the maximum target in-well concentration set to lOOug / ml. The test item was soluble in water.
[0108] The solubility of keratin nano-peptide was assessed. The highest concentration was found to be 100 ug / ml when using water and therefore this vehicle was used for downstream processes. ii. Cytotoxicity assessment:
[0109] For the cytotoxicity assessment, stock solutions in a concentration range were prepared by serial dilution and finally applied concentration ranged from 100 ug / ml to 5.9 ug / ml. Cells were incubated with the test item under standard conditions. After exposure, the cells were stained with pro-indium iodide and cell viability was measured by flow cytometry analysis. Following cellular stimulations, RNA was isolated and endpoint measurements were performed using GARDskin GPS.
[0110] The test item was assayed starting from 100 ug / ml. The results of the cytotoxicity assessment are presented in table 4. No cytotoxicity was observed.
[0111] Table 4: Test item cytotoxicity assessment iii. Phenotypic Quality Control
[0112] To ensure that the cells are maintained in an inactivated state and to detect a potential phenotypic drift, quality control of the cells was performed the day of cell stimulation. The cells passed the specified acceptance criteria in all cell stimulations performed in the study.
[0113] Table 5: The expression of the phenotypic biomarkers in the cell cultures used for the experiments iv. Relative Viability
[0114] The relative viability of the test item, reference item and absolute viability of the unstimulated control were done and presented in table 6. All samples passed the acceptance criteria.
[0115] Table 6: Relative viability of test and reference items
[0116] The concentration was based on maximum solubility and cytotoxicity and the observed viability was calculated based on equation in the Test method. Lastly, the absolute viability is in percentage. v. RNA Quality Control
[0117] RNA quality control was performed in-house by standard methods. The results are presented in table 7 below. All samples passed the acceptance criteria.
[0118] Table 7: Result of RNA quality control
[0119] Conclusion:
[0120] The test item (Keratin nano-peptide) was freely soluble at the maximum in well concentration of lOOug / ml, and no solubility issues were reported. The keratin nano-peptide did not induce cytotoxicity. The positive and negative controls were correctly classified as skin sensitizer and skin non- sensitizer, respectively, in the GARDskin assay. In addition, all specified acceptance criteria were fulfilled in this study, resulting in a valid study.
[0121] Example 7: Allergenicity Assessment of the Keratin Nano-pep tides
[0122] Studies were carried out by the inventors to establish whether the keratine nano peptides as prepared in examples 1 and 2 evokes Active Cutaneous Anaphylaxis (ACA) and / or Immunoglobulin E (IgE)-predominant responses and / or T-cell memory on administration as an alum-adsorbed antigen / immunogen preparation in mice.
[0123] 8-week-old, 22-25g male BALB / c mice were obtained from the Laboratory Animals Facility at CSIR-CDRI after receiving permission to conduct the experiments from the Institutional Animal Ethics Committee. Table 10 provides the details of the control and experimental group of mice as per the experiments performed.
[0124] Table 10: i. Active Cutaneous Anaphylaxis
[0125] The protocol standardized by Inagaki et. al. (Inagaki et. al. 1992) with minor modifications as per Evans et. al. (Evans 2014) was performed. On the day of the terminal sacrifice, Evan’s Blue dye was injected in the tail vein; this was followed by the immunizing antigen (keratin nano peptides, OVA or sterile PBS Negative Control) into the marginal ear vein of the immunized mice to see if anaphylactic shock would be induced. Animals were observed for 15 minutes and euthanized by cervical dislocation; after which the ear pinna was collected to extract Evans’ Blue leached into the tissue. The tissue sample was placed in 1 ml of dimethyl acetamide in 1.5 ml Eppendorff tubes and incubated at 60°C on a dry heating block for 2 hours. The optical density at 608 nm was recorded against a blank which was prepared by extracting the ear pinna of another mouse sacrificed as untreated control for an unrelated experiment.
[0126] Serum IgE and IgG
[0127] Blood was drawn by cardiac puncture and allowed to clot at room temperature. The clot was gently resected and blood serum separated by centrifugation at 1200 rpm for 30 seconds. Serum at indicated dilution were added to ELISA plates coated overnight with lOpg / well of keratin nano peptides in carbonate buffer at pH 9.6 and blocked with 5% fat- free milk. Isotype (IgG or IgE) specific anti-mouse antibodies conjugated to horse radish peroxidase (HRP) were used to reveal Ig of each subtype captured in the wells. Hydrogen peroxide was added as a substrate and TMB as chromogen, the reaction was stopped with H2SO4 and optical density was recorded at 450 nm using a plate reader (PoweWave XS).
[0128] Background-corrected readings of triplicate wells were plotted against serum dilution to find the titre of IgE and IgG antibodies. Averaged OD and standard deviations were plotted using Graphpad Prism. ii. In-vitro Antigen Recall Response
[0129] The popliteal and inguinal lymph nodes (LN) and spleen were harvested aseptically at necropsy. Single-cell suspensions were prepared using hand-held ground glass tissue homogenizers. The cell suspensions were washed by centrifugation in sterile PBS. Erythrocytes were lysed by distilled water osmotic shock, and splenocytes / LN cells were recovered by centrifugation. They were re-suspended in RPML1640 medium purchased from Thermo Fisher Scientific, Cat. No. 11875085 containing 10% FBS. Cells were plated in 96- well culture plates at a density of 105 cells / well. Cells were exposed to keratin nano peptides and OVA at indicated concentrations overnight at 37°C in 5% CO2 incubator.
[0130] Concanavalin A, a T-cell mitogen, was added to the control wells. A fluorescence-based cell proliferation assay kit (Cell Census, Sigma) was used as per the manufacturer’s instructions to estimate cell numbers in different wells after overnight incubation. The numbers did not change appreciably over negative control (no antigen challenge), except in the case of the Concanavalin A positive control. Results and Discussion
[0131] Mice were immunized with either 50pg x 3 doses of OVA; 25 pg or 50 pg of keratin nano peptides or with no protein antigen which was adsorbed on alum adjuvant. As per literature, some may be allergic to chicken eggs (Dhanapala et al. 2015), and chicken egg lysozyme may be considered highly allergenic rather than OVA (Pablos-Tanarro et al. 2018). Therefore, OVA as an appropriate comparator in experimental determination of the relative immunogenicity and allergenic potential of keratin nano peptides was used in this study. i. Active Cutaneous Anaphylaxis is Not Induced by Either keratin nano peptides or OVA
[0132] None of the mice underwent anaphylactic shock and remained mobile and conscious without any sign of stress-induced behavior, gait or appearance. Figure 4 shows a mouse immunized with the higher dose of keratin nano peptides after Evan’s Blue dye was injected in the tail vein.
[0133] The dye in the blood circulatory system imparted a blueish color to the blood vessels visible in the ear of the mouse, as shown in Figure 5. However, the ear tissue itself remained pink and clear of any kind of blue stain prior to the injection of the immunizing or irrelevant antigen in the marginal ear vein.
[0134] The mice ear was injected with lOpg of the immunizing antigen (keratin nano peptides , OVA or sterile PBS Negative Control), without adjuvant in the marginal ear vein of one ear (Figure 6). The animal was observed for 10 minutes. Thereafter, the immunizing antigen was injected subcutaneously in the same ear and observed for another 10 minutes. Finally, the irrelevant antigen (OVA in mice immunized with keratin nano peptides , and vice-versa) was injected in the contralateral ear. In case of induction of anaphylaxis by the immunizing antigen, the blood vessels become leaky, and the skin of the ear stains blue.
[0135] After 15 minutes of injecting either OVA or keratin nano peptides into the ear vein, no blue coloration of the ear was observed. Anaphylaxis usually sets in within a few seconds, however, no dye leaked out of the blood vessels. The mice showed redness of the skin near the site of injection but no sign of dye leaking (Figure 7). ii. Alum-Adsorbed Keratin nano-peptides was a Moderate B-cell Immunogen and Allergen Enzyme-Linked Immunosorbent Assay (ELISA) was performed to study whether alum adsorbed OVA and keratin nano peptides would evoke a B cell response. The ELISA was designed to capture antibodies specific to keratin nano peptides or OVA present in the blood serum of immunized mice. Accordingly, wells in the ELISA plate were coated by overnight incubation with either keratin nano peptides or OVA (lOOpg / ml) at pH 9.6. The coating solution was discarded and residual sites on the plastic surface were blocked with 5% fat- free milk.
[0136] Mouse serum was diluted over a range of 1:100- 1:100,000 and added to the wells for 2 hours at room temperature. The wells were washed and a secondary antibody conjugated to the enzyme horseradish peroxidase (HRP) was added to the wells. The secondary antibody was Ig class- specific: one antibody-enzyme conjugate would bind only mouse IgG and the other, only mouse IgE. Thus, the inventors were able to estimate the relative abundance of the two classes of antibodies in the blood serum of the immunized mice. However, the binding affinities of the IgG-specific and IgE-specific antibody conjugates are not the same, it was not possible to conclude that antibodies of one sub-class were more abundant than the other.
[0137] As shown in Figure 8, neat serum (dilution 100) and dilution by 3, 10 and 30 times resulted in OD of about 2. Further dilution to 100 times extinguished the OD to levels indistinguishable from the background (zero value). For completeness, however, negative values indicating dosedependence are plotted.
[0138] Increasing the immunizing dose to 50pg evoked a dose-dependent increase in both the allergen- induced (IgE) and the immunogen-induced (IgG) responses. Figure 9 depicts the results of the ELISA of the mice immunized with the higher dose.
[0139] The antibody titer in the mice was close to 106, which may be considered as “moderate” in comparison to values as high as 109-1012obtained by active immunization with strong immunogens. It is to be noted, however, that the apparent differences in OD produced by IgG and IgE antibodies respectively between dilutions of 103-105suggested that more IgE was produced by the immunization protocol.
[0140] It still cannot be concluded that the IgE (allergenic) response was stronger than the IgG (immunogenic) response because of the relative flatness of the curves. Thus, while there was clear distinction between the OD generated by serum dilutions of 30, 100, 300, 1000 and 3000 times when they were probed by the IgG-detecting conjugate, the distinction revealed by the IgE-detecting conjugate was less sharp.
[0141] Results
[0142] It can be concluded from the above observations that keratin nano peptides is moderately immunogenic and allergenic. For head-to-head comparison of Keratin nano-peptides with another protein derived from the same species as keratin nano peptides , the inventors carried out parallel experiments using chicken egg albumin or OVA as the immunizing antigen. Only the higher dose-level was tested. It is important to note that the antibody conjugates used for revealing captured antibodies to OA and keratin nano peptides were the same. Differences between OD obtained when either keratin nano peptides or OVA was coated on the ELISA plate had arisen because of the differences between the relative avidities of the anti- keratin nano peptides and anti-OVA antibodies produced by different mice.
[0143] Thus, it is important to keep in mind that dose-dependence and within-group variance of the antibody or B-cell responses have different set of sources of error, not applicable when comparing between groups. In short, the comparison did not distinguish whether one antigen was ‘stronger’ or ‘weaker’ than the other. iii. Alum-Adsorbed OVA was also a Moderate B-cell Immunogen and Allergen
[0144] Figure 10 illustrates the IgG and IgE responses elicited by immunization with OVA. The antibody titer in the mice was about 3xl05. The magnitude of the IgG and IgE response was comparable. However, there was high variability in the IgE responses between animals, as reflected in the large standard deviations. As in the case of Keratin nano-peptides, the data did not provide information about any putative differences between the magnitude of the IgG versus IgE response; and only permit the conclusion that OVA is also a “moderate” immunogen for evoking IgG and IgE responses from B cells. iv. Statistical Analysis of B-Cell Response to check whether OVA was more allergenic.
[0145] One-way ANOVA followed by Tukey’s test for post-hoc comparison of means was carried out on the averaged IgG and IgE responses separately. Levene’s test on squared deviations was carried out to assess homogeneity of variance. Table 8 shows that the IgG responses to 25 or 50pg keratin nano peptides and 50pg OVA were not statistically significantly different at the 0.05 level. Population variances were not significantly different at the 0.05 level, with an F value of 0.70128 and a probability>F=0.50509.
[0146] Table 8: Means comparison using Tukey’s test on IgG responses at alpha =0.05
[0147] Further, Table 9 shows the mean comparison of the IgE responses to different doses of keratin nano peptides and OVA. It was evident that there was no statistically significant difference between animals immunized with low versus high doses of keratin nano peptides ; despite the higher dose eliciting a stronger response. However, there was a statistically significant difference between the response elicited by (the high dose of) OVA when compared with both the low and the high dose of keratin nano peptides . Further the magnitude of the difference was dose-dependent, and OVA elicited a higher (allergenic) response than keratin nano peptides at equivalent dose. Population variances, however, were also significantly different with the F value being 7.4095 and the Probability > F 0.00284.
[0148] Table 9: Means comparison using Tukey’s test on IgE responses at alpha =0.05
[0149] The (actual) statistical power of the ANOVA carried out on IgG responses was 0.12164, while in respect of IgE, it was 0.9603. The results indicate that there was 95% chance that OVA has greater allergenic potential than keratin nano peptides . v. To check whether Alum-Adsorbed keratin nano peptides was a Weak T-cell Immunogen and Allergen
[0150] Single cell suspensions of lymph node (LN) cells and splenocytes recovered from the same mice as described above were exposed to different concentrations of the immunizing antigen, or to the T-cell mitogen Concanavalin A. The in vitro antigen recall response was estimated by a fluorimetric assay of cell proliferation, keratin nano peptides at both low and high doses and OVA elicited a weak recall of the respective antigens. Figures 11-13 depict the results graphically.
[0151] Conclusion
[0152] Immunized animals survived the challenge with soluble antigens without undergoing anaphylactic shock. Neither OVA nor keratin nano peptides induced anaphylaxis when tested in mice that had received one primer and two booster doses of alum-adsorbed antigen; (keratin nano peptides at 25 and 50 pg; OVA at 50 pg) x 3 doses at weekly intervals. It may be concluded that at the doses tested, alum-adsorbed keratin nano peptides is not sufficiently allergenic to induce anaphylaxis.
[0153] Both OVA and keratin nano peptides elicited moderate antibody responses; with OVA generating more antibodies of the immunoglobulin E (IgE) sub-type that is indicative of allergy. It was concluded that keratin nano peptides had lower allergenic potential than egg albumin. Both OVA and keratin nano peptides elicited weak-to-negligible T-cell responses in assays to estimate the ability of T lymphocytes recovered from immunized mice to ‘recall’ the immunizing antigen. It was concluded that keratin nano peptides is a weak T cell antigen. This conclusion was supported by observations of the antibody response, indicating that T cell help was not sufficient to enable a robust antibody response. The inventors speculated that plasma cells giving rise to both IgG and IgE were likely differentiated from B cells with receptors that had germline avidity towards the cognate antigen. In sum, it was concluded that keratin nano peptides is hypoallergenic, with lower allergenic potential than OVA.
[0154] In summary, it can be concluded from the above results that keratin nano peptides is hypoallergenic, with lower allergenic potential than OVA.
[0155] Example 8: Determination of the efficacy of the Keratin Nano-pep tides on hair. Due to the low molecular weight and the small size, the hydrolyzed keratin Nano Peptides go beyond the cuticle, penetrate the hair shaft and reduce damage. When the broken-down protein fills these microscopic gaps, hair gets the strength to minimize damage from chemical treatments, heat styling, mechanical manipulation and the sun. Usually, when hair undergoes chemical processes, the amino acid cysteine breaks down and results in weakened and damaged hair. Keratin Nano-Peptides is known to replace this lost cysteine. Hydrolyzed keratin Nano- Peptides increases cysteine content, which increases tensile strength and minimizes damage. The following study was done to evaluate the efficacy of active biomolecule - keratin nanopeptide on Sensory parameters and effectiveness in repair of damaged hair by analyzing hair texture through SEM, Hair breakage and reduction in split ends.
[0156] A study was carried out on 12 natural black hair tresses to assess the efficacy of the water- soluble keratin nano peptides on the quality of hair. This was a 2-group study.
[0157] Group 1: Test Group (1) active biomolecule - keratin nano-peptide versus Control - 6 tresses.
[0158] Group 2: Control - 6 tresses i. Pre-treatment of Hair tresses
[0159] 12 natural black hair tresses of weight approx. 4-5 gm each and approx. 8-10 inches length were taken. Knots if any were combed and removed. Hair tresses were washed with 20% SLES Solution (approx. 1 ml for 1 tress) to wash off the sebum and debris from the hair tresses. Tresses were dried using a hair dryer. ii. Damaging of hair tresses
[0160] Damaging solution was prepared by adding 9% H2O2 (Quantity to be added will be double as H2O2 is 50% active); 20% Ammonia Solution (Please note: 20% of (25-28)% Active Ammonia Solution, pH around 10.5).
[0161] Hair tresses were dipped in this damaging solution for 1 hour. Hair tresses were removed and rinsed thoroughly with distilled / tap water of 40°C for 5 minutes to wash off any residue of Ammonia and Hydrogen Peroxide. Hair tresses were Tissue / Towel dried and combed again gently to get rid of loose hairs. iii. Baseline Evaluations before treatment for all the groups: The hair tresses were kept at 30°C / 65% RH for approximately 18 hours to condition them. There were two groups Test and Control. Baseline evaluation for Hair Sensory Attributes (Detangling, Combability, Frizz, Visual Shine, Smoothness, Softness and Bounce) was done by 6 experts. Few Strands from each Hair Tress were cut for Tensile Strength Evaluation and SEM images (Figure 13- left most section). 1 minute comb test was done at Baseline for both the Groups. Split ends were evaluated at baseline for both the groups. In Figure 13, it can be observed that the splits were almost negligible as compared to the control. iv. Hair tresses Treatment for Test with active biomolecule - keratin nano-pep tide
[0162] 2 ml of 3% Active Biomolecule - Keratin Nano-peptide was applied on the assigned tresses. The strands were massaged for 1 minute on both sides of the tresses. They were left unattended for a period of 1 hour before washing it. 15% (Sodium Laureth Sulfate) SLES was used for washing the strands, they were dried, and product application was repeated.
[0163] Sensory evaluation after 10 wash cycles for Hair Sensory Attributes (Detangling, Combability, Frizz, Visual Shine, Smoothness, Softness and Bounce) was done by 6 experts. Few Strands from each Hair Tress were cut for Tensile Strength Evaluation and SEM images (Figure 13).1- minute comb test was done after 10 washes for both the Groups. Split ends were evaluated after 10 washes for both the groups. Table 11 also summarizes the keratin nano-peptides against the baseline levels after 10 washes: The results in table 11 indicate that keratin nano-peptides significantly improved the quality of the hair tresses as compared to the control.
[0164] Example 9- Illustrative example elucidating the role of Keratin Nano peptides As Value- Adding Drug Excipient:
[0165] Based on the results of the hypoallergenicity and poor immunogenicity of water soluble and oil soluble keratin nano peptides prepared in example 1 and 2, the inventors hypothesized the use of this material as a safe additive to topical formulations used in management of severe burns.
[0166] The inventors have developed a medicated cream or gel for management of 2nd and 3rd degree burns that would be non-inferior to the Standard of Care (SoC). The cream comprises either the water and / or oil-soluble keratin nano peptides for preparation of tissue engineering scaffolds that are readily colonized by proliferating fibroblasts, chondrocytes, cardiomyocytes and epithelial cells as prepared in examples 1 and 2.
[0167] Figure 14 shows the particle size distribution of keratin nano peptides sample in water. The results demonstrate that the hydrolyzed keratin nano-peptide fragments are distributed around a median diameter of approximately 120nm.
[0168] The foregoing description of the specific embodiments fully reveals the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments in this disclosure have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein.
[0169] Throughout this specification, the word “comprise”, or variations such as “comprises” or “comprising” wherever used, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. Similarly, terms such as “include” or “have” or “contain” and all their variations are inclusive and will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0170] As used herein, the term ‘comprising’ when placed before the recitation of steps in a method means that the method encompasses one or more steps that are additional to those expressly recited, and that the additional one or more steps may be performed before, between, and / or after the recited steps. For example, a method comprising steps a, b, and c encompasses a method of steps a, b, x, and c, a method of steps a, b, c, and x, as well as a method of steps x, a, b, and c. Furthermore, the term “comprising” when placed before the recitation of steps in a method does not (although it may) require sequential performance of the listed steps, unless the content clearly dictates otherwise. For example, a method comprising steps a, b, and c encompasses, for example, a method of performing steps in the order of steps a, c, and b, the order of steps c, b, and a, and the order of steps c, a, and b, etc. The terms "about" or “approximately” are used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical value / range, it modifies that value / range by extending the boundaries above and below the numerical value(s) set forth. In general, the term "about" is used herein to modify a numerical value(s) or a measurable value(s) such as a parameter, an amount, a temporal duration, and the like, above and below the stated value(s) by a variance of + / -20% or less, + / -10% or less, + / -5% or less, + / -1% or less, and + / - 0.1% or less of and from the specified value, insofar such variations are appropriate to perform in the disclosed invention, and achieves the desired results and / or advantages as disclosed in the present disclosure. It is to be understood that the value to which the modifier “about” or “approximately” refers is itself also specifically, and preferably, disclosed.
[0171] With respect to the use of substantially any plural and / or singular terms herein, those having skill in the art can translate from the plural to the singular and / or from the singular to the plural as is appropriate to the context and / or application. The various singular / plural permutations may be expressly set forth herein for sake of clarity. The suffix ‘(s)’ at the end of any term in the present disclosure envisages in scope both the singular and plural forms of said term.
[0172] Numerical ranges stated in the form ‘from x to y’ include the values mentioned and those values that lie within the range of the respective measurement accuracy as known to the skilled person. If several preferred numerical ranges are stated in this form, of course, all the ranges formed by a combination of the different end points are also included.
[0173] As regards the embodiments characterized in this specification, it is intended that each embodiment be read independently as well as in combination with another embodiment. For example, in case of an embodiment 1 reciting 3 alternatives A, B and C, an embodiment 2 reciting 3 alternatives D, E and F and an embodiment 3 reciting 3 alternatives G, H and I, it is to be understood that the specification unambiguously discloses embodiments corresponding to combinations A, D, G; A, D, H; A, D, I; A, E, G; A, E, H; A, E, I; A, F, G; A, F, H; A, F, I;
[0174] B, D, G; B, D, H; B, D, I; B, E, G; B, E, H; B, E, I; B, F, G; B, F, H; B, F, I; C, D, G; C, D, H;
[0175] C, D, I; C, E, G; C, E, H; C, E, I; C, F, G; C, F, H; C, F, I, unless specifically mentioned otherwise.
[0176] Throughout this specification, the term ‘a combination thereof, ‘combinations thereof or ‘any combination thereof or ‘any combinations thereof are used interchangeably and are intended to have the same meaning, as regularly known in the field of patent disclosures.
[0177] Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application.
[0178] While considerable emphasis has been placed herein on the particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. These and other modifications in the nature of the disclosure or the preferred embodiments will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.
[0179] All references, articles, publications, general disclosures etc. cited herein are incorporated by reference in their entireties for all purposes. However, mention of any reference, article, publication etc. cited herein is not, and should not be taken as, an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.
Claims
We claim1. A process for preparing a keratin nano peptides, the process comprising the steps of: a. collecting poultry feathers, followed by hot water rinsing, sterilization and dewaxing to enhance the surface porosity of the feathers obtained in step (a); b. drying and grinding the feathers of step (a) to obtain a fine uniform powder; c. mixing the powder obtained in step (b) with an alkaline solvent and incubated at 45°C- 65°C for 1 to 3 hours in a blender with continuous stirring at 100-200 rpm to obtain the alkaline mixture; d. enzymatically treating the alkaline mixture obtained in step (c) with an enzyme cocktail at 37°C- 50°C for 3 to 5 hours for enzymatic hydrolysis to obtain the post-enzyme hydrolysis extract e. processing the post-enzyme hydrolysis extract of step (d) to obtain the keratin nano peptides wherein the said keratin nano peptides are either water soluble or oil soluble keratin nano peptides.
2. The process as claimed in claim 1, wherein processing step (e) comprises passing the post-enzyme hydrolysis extract obtained in step (d) through a multilevel filtration system to obtain water soluble keratin nano peptides.
3. The process as claimed in claim 2, wherein the multilevel filtration system comprises the steps of passing the enzymatically treated alkaline mixture in a sequential manner through rotary filter, a microfiltration unit and finally through a nanofiltration unit to obtain purified keratin nano-peptides.
4. The process as claimed in claim 1, wherein the processing step (e) comprises a. mixing the post-enzyme hydrolysis extract obtained in step (d) with a fatty acid ester in a vessel at 60-80°C overnight. b. adding a 2ndfatty acid ester dissolved in an alcohol to the reaction mixture obtained in step (a) for 3-5 hours at temperature 60-80°C;c. raising the temperature to 80-90°C of the solution obtained in step (b) for 2-6 hours; and d. filtering the solution obtained in step (c) to obtain the oil soluble keratin nano peptides.
5. The process for production of oil-soluble keratin nano-peptides as claimed in claim 4, wherein the oil-soluble keratin nano-peptide obtained in step (d) is filtered with an inline filter membrane.
6. The process as claimed in claim 1, wherein the enzyme cocktail of step (d) is an enzymatic concoction of at least two or more fungal or plant protease enzymes.
7. The process as claimed in claim 6, wherein the two or more protease enzymes are in the concentration range of 0.2 to 3.5.
8. The process as claimed in claim 1, wherein the fungal protease enzymes are obtained from the group consisting of genera Aspergillus, Penicillium, or Rhizopus.
9. The process as claimed in claim 1, wherein the protease in enzyme cocktail is obtained from at least 2 proteases selected from aspartic, glutamic, metalloproteases, cysteine, serine, and threonine proteases or combinations thereof.
10. The process as claimed in claim 1, wherein the alkaline solvent of step (c) is selected from sodium hydroxide, potassium hydroxide and calcium hydroxide.
11. The process as claimed in claim 1, wherein the alkaline solvent is in the range of 1-5%.
12. A multilevel filtration process for obtaining the nano-keratin nano- peptide, wherein the process comprises the steps of: a. passing the solution post enzyme hydrolysis extract obtained in step (e) of claim 1 through a rotary filter having a sieve of at most 50p to obtain a solution free of any bigger size particles, b. passing the solution of step (a) through a microfiltration unit a ceramic filter of at most 0.2 microns andc. passing the extract from step (b) through a nanofiltration unit with a cut off of 300 kDa molecular level size to obtain the final concentrated product which is a water-soluble keratin nano peptides.
13. A multi-level filtration system comprising: a rotary filter (100) having a sieve size of 50 microns; microfiltration unit having a sieve size of .02 microns; and nanofiltration unit having a sieve size of a minimum of 300 kDa; wherein the concentrate is transported from the feed storage tank (101) through a recirculation pump (102) to the ceramic membrane system (103); the permeate is collected in the permeate tank (104) and transported by the feed pump (105) to the MCF (106); the nanofiltration high pressure pump (107) transfers the permeate to the nanofiltraton membrane system (108) and the concentrate is collected; the permeate is then stored in a permeate storage tank (109).
14. A water-soluble keratin nano- peptide obtained from the process as claimed in claim 2, wherein the keratin nano- peptide has a molecular weight range of 500Da to 30kDa.
15. An oil-soluble keratin nano- peptide obtained from the process as claimed in 4 wherein the keratin nano- peptide has a molecular weight range of 500Da to 30kDa.
16. The keratin nano- peptide as claimed in claim 14 and 15, wherein the size of the keratin nano-peptides is in the range of l-5nm.
17. A composition comprising the keratin nano-peptide along with pharmaceutically acceptable excipients, diluent and carriers.
18. The composition as claimed in claim 17, wherein the pharmaceutically acceptable excipients or carriers are any selected from disaccharides, polysaccharides, sugar alcohol, gum, humectants, emulsifiers, emollients, preservatives, water, cellulose starch, maltodextrin, essential oils or combinations thereof.
19. The composition as claimed in claim 17, wherein the composition is formulated in the form of shampoos, serums, hair and scalp care products, supplements and nutraceutical formulation.
20. The keratin nano-peptide as claimed in claim 14 and 15 as and when employed in nutraceutical, pharmaceutical and cosmetics industry, or as an excipient for formulation in a drug delivery system.
21. The composition as claimed in claim 17, as and when used in the preparation of tissue engineering scaffolds or for preparation of medicated creams or gels for management of 2nd and 3rd degree bums.
Citation Information
Patent Citations
Method for preparing feather protein powder from alkaline protease / keratinase
CN104798981A
Hydrolyzed feather meal additive and application thereof to animal feed
CN109965086A
Process for extraction of keratin
IN202121048592A
Keratin Hydrolysates, Process for Their Production and Cosmetic Composition Containing the Same
US20100196302A1
Methods and uses for keratin hydrolysis
US20180263259A1
